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the 6 agencies (9 publications) that evaluated DPP-4 inhibitors, 2 recommended the 
drug not be listed or funded (CADTH, AHTAPol) and 4 recommended restricted use 
(PBAC, SMC, CVZ and NICE). The most common reason for agency’s disinclination 
for listing/funding was insufﬁcient information on the effectiveness and cost-effective-
ness in the speciﬁed patient population. There are more than 100 HTAs ongoing in 
the endocrine nutritional and metabolic therapeutic area, approximately half of them 
(49 projects) concern diabetes, 21 of which evaluate pharmacological treatment of 
diabetes (8 countries, 11 agencies). CONCLUSIONS: Diabetes prevalence is on the 
rise, attracting increasing attention from health care agencies. Despite using similar 
data sources variable outcomes suggest to us that agencies are applying different 
weightings in their assessment process. The apparent failure to demonstrate effective-
ness in speciﬁed populations suggests late segmentation by manufacturers and insufﬁ-
cient resourcing to generate data. This is often due to late payer requests for such 
analyses motivated by ﬁnancial considerations. Early segmentation and engagement 
with payers is thus critical for HTA success.
PDB76
ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF 
DIABETES TREATMENTS
Kaas C1, Jensen RCØ2, Adalsteinsson E3
1Copenhagen University, Copenhagen, Denmark, 2Novo Nordisk A/S, Bagsværd, Denmark, 
3Novo Nordisk A/S, Soeborg, Denmark
OBJECTIVES: Health Technology Assessment (HTA) is mostly known for its health 
economic properties even though it is a multidisciplinary form of policy research 
examining short- and long-term consequences of the application of a health technol-
ogy. There is an increased focus on ethical analyses in HTA. A descriptive analysis 
was conducted on diabetes HTA reports describing ethical analyses. METHODS: The 
NHS Centre for Reviews and Dissemination HTA database (http://www.crd.york.
ac.uk/crdweb/) was searched (1991–2009) using the keyword ‘diabet*’. HTA reports 
in English language assessing diabetes treatments were included and screened for any 
type of ethical analyses. RESULTS: Of 263 HTA reports identiﬁed in the initial search, 
60 met the inclusion criteria. 4 reports included a type of ethical analysis (2 from 
CADTH, Canada; 1 from AHTA, Australia and 1 from NZHTA, New Zealand). 
CADHT conducted ethical analyses on short- and long-acting insulin analogues 
respectively, concluding that both types of insulin analogues did not exacerbate—
might even better—the psychosocial issues of diabetes, however more quality-of-life        
evidence were needed. In AHTA’s assessment of a continuous glucose monitoring 
device they described equity and access issues related to costs, and that the device 
could not replace standard of care, but should be used as an adjunct. NZHTA’s 
assessment of continuous glucose monitoring devices was also related to equity con-
cerns, concluding a need for more affordable devices. CONCLUSIONS: Ethical analy-
ses are sparse in diabetes, despite stated objectives of best practice and HTA deﬁnitions. 
In the identiﬁed cases, ethical analyses were targeted to meet patients’ needs as well 
as a tool to restrict access for the purpose of fair distribution in government funded 
health care systems. Further research on the methods of ethical analyses is warranted 
as well as the formulation of guidelines to fully estimate the value and ensure an 
optimal role for ethical analyses in HTA.
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OBJECTIVES: The ongoing Cardiovascular (CV) Risk Evaluation in people with 
Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is assessing the 
effect of insulin on the risk of vascular events. METHODS: CREDIT is a 4-year, 314 
centre, non-interventional trial in North America, Europe and Asia, and includes 3031 
people with T2DM who recently started basal and/or short-acting insulin, premix 
insulin or another insulin type. This analysis examines and compares the characteris-
tics between groups starting basal (n  1563), basal  short-acting (n  444), short-
acting (n  221), premixed (n  700) or another (n  103) insulin. RESULTS: 
Demographic and diabetes characteristics were reasonably balanced between the 
insulin groups, although those receiving basal plus short-acting insulin or premix had 
a trend to higher baseline HbA1c levels vs other insulin types (basal, 9.2 o 1.8%; basal 
 short-acting, 10.1 o 2.2%; short-acting, 9.4 o 2.0%; premix, 9.9 o 2.0%; other, 9.1 
o 2.0%). While the majority had previously used oral glucose lowering drugs (OGLDs) 
(basal, 97%; basal  short-acting, 83%; short-acting, 83%; premix, 94%; other, 
85%), differences in the numbers continuing OGLDs when beginning insulin were 
found. Continued use of OGLDs was highest wth basal insulin (89%) versus the other 
insulins (basal  short-acting, 36%; short-acting, 45%; premix, 62%; other, 34%). 
However, the distribution of types of OGLD used before insulin was similar between 
the groups. There are no clear patterns in CV risk proﬁle by insulin type. Previous 
diagnosis of hypertension (basal, 71%; basal  short-acting, 65%; short-acting, 57%; 
premix, 69%; other, 72%), family history of CV disease (basal, 29%; basal  short-
acting, 25%; short-acting, 21%; premix, 23%; other, 14%) and body mass index 
tended to be lower in the short-acting insulin group. However, triglyceride levels were 
lower in the short-acting and ‘other’ insulin groups vs premix, basal and basal 
plus short-acting groups. CONCLUSIONS: People starting different insulins have 
somewhat different clinical characteristics, which may confound attempts to compare 
future vascular outcomes between regimens.
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OBJECTIVES: Maintaining long-term glycaemic control with insulin therapy can 
reduce the risk of vascular events associated with Type-2 diabetes mellitus (T2DM). 
The Cardiovascular (CV) Risk Evaluation in people with T2DM on Insulin Therapy 
(CREDIT) study is an ongoing 4-year, noninterventional trial in 314 centres across 
North America, Europe and Asia. METHODS: People with T2DM who recently 
started insulin were included. Here we report variation in baseline characteristics of 
participants in eastern vs northern vs southern Europe. RESULTS: Marked differences 
in participant characteristics were found between eastern Europe (n  735), northern 
(n  460) and southern Europe (n  647), including proportion of males (25 vs. 61 
vs. 56%), diabetes duration (8 o 5 vs. 9 o 6 vs. 13 o 9 years), age (58 o 8 vs. 63 o 
11 vs. 63 o 11 years) and HbA1c (9.7 o 1.9 vs. 9.1 o 2.0 vs. 9.3 o 1.9%). Combina-
tions of oral glucose-lowering drugs were common before insulin; sulfonylureas were 
dominant in eastern Europe and metformin elsewhere. Over 80% were taking non-
glucose medications before insulin initiation, most commonly ARBs. People in eastern 
Europe had a greater family history of CV disease, were less physically active, but 
were not more obese (BMI: 30.7 o 5.4 vs. 31.5 o 6.3 vs. 29.6 o 5.9 kg/m2). Rates of 
hypertension were lowest in southern Europe. HDL cholesterol in males was lowest 
in northern Europe and in females was highest in eastern Europe. LDL cholesterol 
was highest in southern Europe. Total cholesterol levels were lowest, but triglyceride 
levels were highest in northern Europe. Smoking was less prevalent in eastern Europe. 
Most people began with a basal insulin regimen (60 vs 63 vs. 62%); more people used 
meal-time insulin in eastern Europe (19 vs. 11 vs. 17%) and pre-mixes in northern 
Europe (22 vs. 28 vs. 13%). CONCLUSIONS: Baseline characteristics of people start-
ing insulin reveals some striking differences between European regions; how these 
translate into CV events as the study progresses will be of interest.
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OBJECTIVES: The Cardiovascular Risk Evaluation in people with Type-2 diabetes 
mellitus (T2DM) on Insulin Therapy (CREDIT) study is evaluating the effect of insulin 
on the risk of vascular events, which can be reduced via long-term glycaemic control. 
METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North 
America, Europe and Asia. It includes 3031 people with T2DM who had recently 
started basal, short-acting or premix insulin, over half of whom received basal insulin 
alone (n  1563). This analysis examines the baseline characteristics amongst the 
subgroup initiating basal insulin after oral failure and compares them with those of 
the wider CREDIT population. RESULTS: The mean starting dose of basal insulin 
was 14.7 IU/day, administered once daily in 86% of participants. Of these, 61% took 
their injection at bedtime, 21% at breakfast, 17% at dinner and 1% at lunch. Over 
90% used pen devices, split equally between disposable (46%) and reusable devices 
(45%). Demographic and clinical characteristics, including macrovascular disease and 
cardiovascular risk proﬁles, were broadly similar between the basal insulin subgroup 
and the overall group of participants (basal insulin subgroup vs total population: 
males, 48 vs 51%; age, 62 o 11 vs 61 o 10 years; T2DM duration, 10 o 7 vs 11 o 8 
years; HbA1c, 9.2 o 1.8 vs 9.5 o 2.0%; prior use of oral glucose lowering drugs 
[OGLDs], 97 vs 93%). Use of OGLDs with insulin tended to be higher in the basal 
insulin subgroup than in the total population (any OGLD, 89 vs. 70%; biguanides, 
64 vs. 50%, sulfonylureas, 63 vs. 43%). CONCLUSIONS: The one notable difference 
between the groups was that those beginning basal insulin alone were more heavily 
treated with OGLDs beforehand than in the overall population, most commonly bigu-
anides and sulfonylureas. This suggests that they required no lesser intensity of gly-
caemic management than people starting on other types of insulin.
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OBJECTIVES: The 2008/09 Quality and Outcomes Framework (QOF) indicators for 
measuring glycosylated haemoglobin (HbA1c) levels are DM20 and DM07, which 
measure percentage of diabetic patients with HbA1c of either 7.5 or less or 10 or less 
respectively. New QOF clinical indicators have been agreed for 2009/10: DM23 
